Navigation Links
Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
Date:5/3/2017

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has appointed Josh Blacher as Chief Financial Officer, effective immediately.

Mr. Blacher joins Therapix with ten years of experience in senior financial and business development related positions at publicly-traded biotechnology and pharmaceutical companies, as well as 14 years in capital markets in the United States.  Prior to joining Therapix, Mr. Blacher served as Chief Financial Officer at Galmed Pharmaceuticals (NASDAQ: GLMD).  Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers.  Mr. Blacher holds an MBA in Finance from Columbia Business School.

"Now that Therapix has completed its U.S. IPO and NASDAQ listing, and initiated additional clinical trials, it is clear that we will need someone of Josh's caliber to help us develop and bring awareness of our growth strategy to the U.S. capital markets, as well as monetize our assets globally.  We're confident that Josh's broad-based experience and track record will help us accomplish our objectives," commented Dr. Elran Haber, Therapix's Chief Executive Officer and Dr. Ascher Shmulewitz, the Company's Executive Chairman.  Drs. Haber and Shmulewitz continued, "We're delighted to welcome Josh to the company."

"Therapix has all the makings of a successful specialty pharmaceutical company – compelling technology in areas of high unmet medical needs, strong management and long-term investors, as well as the financial wherewithal to execute its strategy," commented Mr. Blacher.  "I am very excited to join Therapix and look forward to helping the company unlock its significant potential."

About Therapix Biosciences

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma, developing THX-TS01 targeted to the treatment of Tourette's syndrome; and BrainBright Pharma, developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments. More information is available online at http://www.therapixbio.com.

Forward-Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss accomplishing our objectives and that we have the financial wherewithal to execute our strategy. These forward-looking statements involve certain risks and uncertainties, including, among others, risks that could cause the Company's results to differ materially from those expected by Company management or otherwise described in or implied by the statements in this press release. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is available on the SEC's website, http://www.sec.gov.

For further information: Investor Contact:
Josh Blacher, CFO
Therapix Biosciences
josh@therapixbio.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-announces-the-appointment-of-josh-blacher-as-chief-financial-officer-300450536.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. Northstar Biosciences Launches All Natural Skincare Solutions
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
7. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/9/2019)... ... 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture ... to image through and therefore traditional wide-field or even confocal microscopy only tells you ...
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
Breaking Biology Technology:
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... a computational modeling system that could have far-reaching implications for personalized medicine, especially ... squares regression (PLSR), is able to predict which stem cell donors and manipulation ...
Breaking Biology News(10 mins):